Golden
Lyell Immunopharma

Lyell Immunopharma

A biotechnology company developing cellular immunotherapies for treating cancer.

Lyell Immunopharma is a biotechnology company developing targeted cellular immunotherapies for treating any type of cancer that is headquartered in San Francisco, California and was founded in 2018 by Rick Klausner. The companies cellular immunotherapy products focus on using chimeric antigen receptor T (CAR-T) cells to treat solid tumors (which make up the majority of cancers). As of June 2019 the company has not publicly disclosed its official product pipeline despite receiving series A and series B funding from private investors.

Funding

Series A

On November 13, 2018 Lyell Immunopharma completed their series A funding round with an undisclosed amount of funding from undisclosed investors. The company is planning on using their series A funding for product development. 

Series B

On February 8, 2019 Lyell Immunopharma completed their series B funding round with $179 million in funding from 8VC, Altitude Life Science Ventures, ARCH Venture Partners, Forsite Capital Management, and BMGI. 

Timeline

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References